Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 59 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. Teriparatide: Shock and loss of consciousness. Japan . WHO Drug Information 2018;32:18. [Ref.ID 102621]
2. Cita con resumen
Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ, Wermers RA. Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab 2016;101:1166-73. [Ref.ID 100079]
3.Tiene citas relacionadas Cita con resumen
Malhi GS. Lithium therapy in bipolar disorder: a balancing act?. Lancet 2015;386:415-6. [Ref.ID 99396]
4.Tiene citas relacionadas
Bischoff-Ferrari HA, Meyer O. Comparative effectiveness of pharmacologic treatments to prevent fractures: is this all we need to know?. Ann Intern Med 2014;161:711-23. [Ref.ID 98329]
5.Tiene citas relacionadas Cita con resumen
Crandall CJ, Newberry SJ, Diamant A, Lim Y-W, Gellad WF, Booth MJ, Motala A, Shekelle PG. Comparative effectiveness of pharmacologic treatments to prevent fractures: and updated systematic review. Ann Intern Med 2014;161:711-23. [Ref.ID 98328]
6. Cita con resumen
Anónimo. Cinacalcet: fatal paediatric hypocalcaemia. United Kingdom. WHO Drug Information 2013;27:105-6. [Ref.ID 95810]
7. Cita con resumen
García Doladé N, Cereza García G, Madurga M, Montero Corominas D. Riesgo de hipercalcemia e hipervitaminosis D por calcifediol. Revisión de casos notificados al Sistema Español de Farmacovigilancia. Med Clin (Barc) 2013;141:88-9. [Ref.ID 95766]
8. Cita con resumen
Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, Tonelli M. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials . PLOS Medicine 2013;10:1. [Ref.ID 95325]
9.
Pallan S, Rahman MO, Khan AA. Diagnosis and management of primary hyperparathyroidism. BMJ 2012;344:55-60. [Ref.ID 92652]
10. Cita con resumen
Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R. Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2010;153:815-25. [Ref.ID 89876]
11. Cita con resumen
Schwartz LM, Woloshin S. Lost in transmission — FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20. [Ref.ID 86923]
12. Cita con resumen
Anónimo. Insuffisances rénales d'origine médicamenteuse. Prescrire 2009;29:506-10. [Ref.ID 86213]
14. Cita con resumen
LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008;149:259-63. [Ref.ID 83814]
15. Cita con resumen
Sutter S. Edetate disodium products wihdrawn. Scrip 2008;3371:20. [Ref.ID 83308]
16. Cita con resumen
Brett AS. Should we be concerned about jaw osteonecrosis with oral bisphosphonates?. Journal Watch 2008;28:71-2. [Ref.ID 82776]
17.Tiene citas relacionadas
Ma RCW, Kong APS, Chan N, Tong PCY, Chan JCN. Drug-induced endocrine and metabolic disorders. Drug Saf 2007;30:215-45. [Ref.ID 79583]
18. Cita con resumen
Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, for the Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. A randomized trial. Ann Intern Med 2007;146:326-39. [Ref.ID 79534]
19.
Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006;29:1133-52. [Ref.ID 78777]
20.
Seleccionar todas
 
 1 a 20 de 59 siguiente >>